Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AE Indole derivatives
N05AE05 Lurasidone
D04820 Lurasidone hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Lurasidone
D04820 Lurasidone hydrochloride (JAN/USAN)
Bipolar Agents
Bipolar Agents, Other
Lurasidone
D04820 Lurasidone hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D04820 Lurasidone hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01483 5-HT1A-receptor agonist
D04820 Lurasidone hydrochloride
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
D04820 Lurasidone hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D04820 Lurasidone hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D04820 Lurasidone hydrochloride (JAN/USAN) <JP/US>
Serotonin
HTR2A
D04820 Lurasidone hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04820
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04820
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04820
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04820
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04820